- Home
- ALLR
as 07-26-2024 4:00pm EST
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 10.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -410.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.14 - $69.00 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Allarity Therapeutics Inc. News
ALLR Breaking Stock News: Dive into ALLR Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 hours ago
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
GlobeNewswire
3 days ago
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
GlobeNewswire
5 days ago
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
GlobeNewswire
a month ago
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
GlobeNewswire
a month ago
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
GlobeNewswire
2 months ago
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
GlobeNewswire
2 months ago
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
Zacks
3 months ago
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
Compare ALLR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLR Allarity Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.